Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies. Its clinical utility as an oral anticancer agent, however, is limited by poor oral bioavailability and gastrointestinal toxicity. Fosc...

Descripción completa

Detalles Bibliográficos
Autores principales: Weir, Scott J., Dandawate, Prasad, Standing, David, Bhattacharyya, Sangita, Ramamoorthy, Prabhu, Rangarajan, Parthasarathy, Wood, Robyn, Brinker, Amanda E., Woolbright, Benjamin L., Tanol, Mehmet, Ham, Tammy, McCulloch, William, Dalton, Michael, Reed, Gregory A., Baltezor, Michael J., Jensen, Roy A., Taylor, John A., Anant, Shrikant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166826/
https://www.ncbi.nlm.nih.gov/pubmed/34059639
http://dx.doi.org/10.1038/s41419-021-03836-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166826/
https://www.ncbi.nlm.nih.gov/pubmed/34059639
http://dx.doi.org/10.1038/s41419-021-03836-z

Ejemplares similares